512 related articles for article (PubMed ID: 29316631)
1. Psoriasis: A STAT3-Centric View.
Calautti E; Avalle L; Poli V
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29316631
[TBL] [Abstract][Full Text] [Related]
2. Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway.
Loo WJ; Turchin I; Prajapati VH; Gooderham MJ; Grewal P; Hong CH; Sauder M; Vender RB; Maari C; Papp KA
J Cutan Med Surg; 2023; 27(1_suppl):3S-24S. PubMed ID: 36519621
[TBL] [Abstract][Full Text] [Related]
3. Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution.
Bharadwaj U; Kasembeli MM; Robinson P; Tweardy DJ
Pharmacol Rev; 2020 Apr; 72(2):486-526. PubMed ID: 32198236
[TBL] [Abstract][Full Text] [Related]
4. Psoriatic inflammation enhances allergic airway inflammation through IL-23/STAT3 signaling in a murine model.
Nadeem A; Al-Harbi NO; Ansari MA; Al-Harbi MM; El-Sherbeeny AM; Zoheir KMA; Attia SM; Hafez MM; Al-Shabanah OA; Ahmad SF
Biochem Pharmacol; 2017 Jan; 124():69-82. PubMed ID: 27984001
[TBL] [Abstract][Full Text] [Related]
5. Berberine downregulates CDC6 and inhibits proliferation via targeting JAK-STAT3 signaling in keratinocytes.
Sun S; Zhang X; Xu M; Zhang F; Tian F; Cui J; Xia Y; Liang C; Zhou S; Wei H; Zhao H; Wu G; Xu B; Liu X; Yang G; Wang Q; Zhang L; Gong Y; Shao C; Zou Y
Cell Death Dis; 2019 Mar; 10(4):274. PubMed ID: 30894513
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23/IL-17 axis.
Works MG; Yin F; Yin CC; Yiu Y; Shew K; Tran TT; Dunlap N; Lam J; Mitchell T; Reader J; Stein PL; D'Andrea A
J Immunol; 2014 Oct; 193(7):3278-87. PubMed ID: 25156366
[TBL] [Abstract][Full Text] [Related]
7. Astilbin inhibits Th17 cell differentiation and ameliorates imiquimod-induced psoriasis-like skin lesions in BALB/c mice via Jak3/Stat3 signaling pathway.
Di TT; Ruan ZT; Zhao JX; Wang Y; Liu X; Wang Y; Li P
Int Immunopharmacol; 2016 Mar; 32():32-38. PubMed ID: 26784569
[TBL] [Abstract][Full Text] [Related]
8. Selective Immunomodulation of Inflammatory Pathways in Keratinocytes by the Janus Kinase (JAK) Inhibitor Tofacitinib: Implications for the Employment of JAK-Targeting Drugs in Psoriasis.
Morelli M; Scarponi C; Mercurio L; Facchiano F; Pallotta S; Madonna S; Girolomoni G; Albanesi C
J Immunol Res; 2018; 2018():7897263. PubMed ID: 30581877
[TBL] [Abstract][Full Text] [Related]
9. Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis.
Roskoski R
Pharmacol Res; 2023 Mar; 189():106642. PubMed ID: 36754102
[TBL] [Abstract][Full Text] [Related]
10. Studies of Jak/STAT3 expression and signalling in psoriasis identifies STAT3-Ser727 phosphorylation as a modulator of transcriptional activity.
Andrés RM; Hald A; Johansen C; Kragballe K; Iversen L
Exp Dermatol; 2013 May; 22(5):323-8. PubMed ID: 23614738
[TBL] [Abstract][Full Text] [Related]
11. Oral administration of a novel RORγt antagonist attenuates psoriasis-like skin lesion of two independent mouse models through neutralization of IL-17.
Takaishi M; Ishizaki M; Suzuki K; Isobe T; Shimozato T; Sano S
J Dermatol Sci; 2017 Jan; 85(1):12-19. PubMed ID: 27726924
[TBL] [Abstract][Full Text] [Related]
12. Inhibiting ex-vivo Th17 responses in Ankylosing Spondylitis by targeting Janus kinases.
Hammitzsch A; Chen L; de Wit J; Al-Mossawi MH; Ridley A; Sekine T; Simone D; Doig K; Skapenko A; Bowness P
Sci Rep; 2018 Oct; 8(1):15645. PubMed ID: 30353145
[TBL] [Abstract][Full Text] [Related]
13. Heme oxygenase-1 directly binds STAT3 to control the generation of pathogenic Th17 cells during neutrophilic airway inflammation.
Lin XL; Lv JJ; Lv J; Di CX; Zhang YJ; Zhou T; Liu JL; Xia ZW
Allergy; 2017 Dec; 72(12):1972-1987. PubMed ID: 28580587
[TBL] [Abstract][Full Text] [Related]
14. Antrodia cinnamomea Extract Inhibits Th17 Cell Differentiation and Ameliorates Imiquimod-Induced Psoriasiform Skin Inflammation.
Li MH; Wu HC; Yao HJ; Lin CC; Wen SF; Pan IH
Am J Chin Med; 2015; 43(7):1401-17. PubMed ID: 26477794
[TBL] [Abstract][Full Text] [Related]
15. Critical role of the interleukin-23/T-helper 17 cell axis in the pathogenesis of psoriasis.
Nakajima K
J Dermatol; 2012 Mar; 39(3):219-24. PubMed ID: 22352845
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-23 and interleukin-17: importance in pathogenesis and therapy of psoriasis.
Mudigonda P; Mudigonda T; Feneran AN; Alamdari HS; Sandoval L; Feldman SR
Dermatol Online J; 2012 Oct; 18(10):1. PubMed ID: 23122008
[TBL] [Abstract][Full Text] [Related]
17. Newer treatments of psoriasis regarding IL-23 inhibitors, phosphodiesterase 4 inhibitors, and Janus kinase inhibitors.
Wcisło-Dziadecka D; Zbiciak-Nylec M; Brzezińska-Wcisło L; Bebenek K; Kaźmierczak A
Dermatol Ther; 2017 Nov; 30(6):. PubMed ID: 28994166
[TBL] [Abstract][Full Text] [Related]
18. 17-hydroxy-jolkinolide B inhibits signal transducers and activators of transcription 3 signaling by covalently cross-linking Janus kinases and induces apoptosis of human cancer cells.
Wang Y; Ma X; Yan S; Shen S; Zhu H; Gu Y; Wang H; Qin G; Yu Q
Cancer Res; 2009 Sep; 69(18):7302-10. PubMed ID: 19706767
[TBL] [Abstract][Full Text] [Related]
19. Treatment of psoriasis: janus kinases inhibitors and biologics for the interleukin-23/Th17 axis.
Sun C; Xia J
Minerva Med; 2020 Jun; 111(3):254-265. PubMed ID: 32166932
[TBL] [Abstract][Full Text] [Related]
20. Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor PF-06700841 Reveal Reduction of Skin Inflammation in Plaque Psoriasis.
Page KM; Suarez-Farinas M; Suprun M; Zhang W; Garcet S; Fuentes-Duculan J; Li X; Scaramozza M; Kieras E; Banfield C; Clark JD; Fensome A; Krueger JG; Peeva E
J Invest Dermatol; 2020 Aug; 140(8):1546-1555.e4. PubMed ID: 31972249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
